Marko Anderluh

2.8k total citations
105 papers, 2.1k citations indexed

About

Marko Anderluh is a scholar working on Molecular Biology, Organic Chemistry and Immunology. According to data from OpenAlex, Marko Anderluh has authored 105 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 31 papers in Organic Chemistry and 24 papers in Immunology. Recurrent topics in Marko Anderluh's work include Glycosylation and Glycoproteins Research (21 papers), Cancer therapeutics and mechanisms (15 papers) and Antibiotic Resistance in Bacteria (13 papers). Marko Anderluh is often cited by papers focused on Glycosylation and Glycoproteins Research (21 papers), Cancer therapeutics and mechanisms (15 papers) and Antibiotic Resistance in Bacteria (13 papers). Marko Anderluh collaborates with scholars based in Slovenia, Serbia and Netherlands. Marko Anderluh's co-authors include D. Kikelj, Urban Švajger, Nataša Obermajer, Marija Sollner Dolenc, Tihomir Tomašič, Andrija Šmelcerović, Janez Ilaš, Gordana Kocić, Matjaž Jeras and Katarina Tomović and has published in prestigious journals such as Nature Communications, PLoS ONE and Analytical Biochemistry.

In The Last Decade

Marko Anderluh

102 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marko Anderluh Slovenia 26 1.2k 774 343 190 178 105 2.1k
Sonsoles Martín‐Santamaría Spain 31 1.3k 1.1× 835 1.1× 621 1.8× 153 0.8× 106 0.6× 93 2.6k
Tihomir Tomašič Slovenia 31 1.7k 1.4× 1.4k 1.8× 176 0.5× 172 0.9× 205 1.2× 129 3.0k
Andreas Larsson Sweden 21 1.9k 1.6× 473 0.6× 200 0.6× 397 2.1× 162 0.9× 55 2.9k
Koji Tomita Japan 29 1.2k 1.0× 574 0.7× 119 0.3× 218 1.1× 634 3.6× 125 2.6k
Nickolay Y. Chirgadze United States 24 1.2k 1.0× 443 0.6× 194 0.6× 259 1.4× 106 0.6× 38 2.0k
Arnab K. Chatterjee United States 30 1.7k 1.4× 1.0k 1.3× 163 0.5× 319 1.7× 113 0.6× 76 3.5k
Yuzuru Akamatsu Japan 25 1.4k 1.2× 311 0.4× 534 1.6× 138 0.7× 281 1.6× 90 2.5k
Louis Grenier Canada 22 1.6k 1.3× 689 0.9× 166 0.5× 552 2.9× 248 1.4× 42 2.5k
Ramón Hurtado‐Guerrero Spain 34 2.1k 1.8× 965 1.2× 531 1.5× 160 0.8× 63 0.4× 122 3.0k
Debashis Mitra India 31 1.1k 0.9× 406 0.5× 956 2.8× 142 0.7× 124 0.7× 99 2.8k

Countries citing papers authored by Marko Anderluh

Since Specialization
Citations

This map shows the geographic impact of Marko Anderluh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marko Anderluh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marko Anderluh more than expected).

Fields of papers citing papers by Marko Anderluh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marko Anderluh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marko Anderluh. The network helps show where Marko Anderluh may publish in the future.

Co-authorship network of co-authors of Marko Anderluh

This figure shows the co-authorship network connecting the top 25 collaborators of Marko Anderluh. A scholar is included among the top collaborators of Marko Anderluh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marko Anderluh. Marko Anderluh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tomašič, Tihomir, Jurij Lah, Anders Sundin, et al.. (2025). Nanomolar inhibitor of the galectin-8 N-terminal domain binds via a non-canonical cation-π interaction. Communications Chemistry. 8(1). 59–59. 1 indexed citations
2.
Tomašič, Tihomir, et al.. (2024). Discovery of two non-UDP-mimic inhibitors of O-GlcNAc transferase by screening a DNA-encoded library. Bioorganic Chemistry. 147. 107321–107321. 1 indexed citations
3.
Tomašič, Tihomir, et al.. (2024). New Inhibitors of β‐1,4‐Galactosyltransferase I Discovered by Virtual Screening. ChemMedChem. 20(7). e202400896–e202400896. 1 indexed citations
4.
Håkansson, M., Richard Johnsson, Žiga Jakopin, et al.. (2024). Galectin-8N-Selective 4-Halophenylphthalazinone-Galactals Double π-Stack in a Unique Pocket. ACS Medicinal Chemistry Letters. 15(8). 1319–1324. 2 indexed citations
5.
Kramer, Lovro, et al.. (2024). Modulating antibody N-glycosylation through feed additives using a multi-tiered approach. Frontiers in Bioengineering and Biotechnology. 12. 1448925–1448925. 1 indexed citations
6.
Tomašič, Tihomir, et al.. (2023). Design of OSMI‐4 Analogs Using Scaffold Hopping: Investigating the Importance of the Uridine Mimic in the Binding of OGT Inhibitors. ChemMedChem. 18(8). e202300001–e202300001. 5 indexed citations
7.
8.
Tomašič, Tihomir, Martina Gobec, Matthew G. Alteen, et al.. (2022). Discovery of a New Drug-like Series of OGT Inhibitors by Virtual Screening. Molecules. 27(6). 1996–1996. 5 indexed citations
9.
Knez, Damijan, Izidor Sosič, Janez Mravljak, et al.. (2022). Repurposing of 8‐Hydroxyquinoline‐Based Butyrylcholinesterase and Cathepsin B Ligands as Potent Nonpeptidic Deoxyribonuclease I Inhibitors. ChemMedChem. 17(5). e202100694–e202100694. 6 indexed citations
10.
Jakopin, Žiga, et al.. (2022). Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors. RSC Advances. 12(29). 18973–18984. 6 indexed citations
11.
Sundin, Anders, M. Håkansson, Hakon Leffler, et al.. (2021). Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. ACS Medicinal Chemistry Letters. 12(11). 1745–1752. 10 indexed citations
12.
Sundin, Anders, Žiga Jakopin, Marko Anderluh, et al.. (2021). Selective Galectin‐8N Ligands: The Design and Synthesis of Phthalazinone‐d‐Galactals. ChemMedChem. 17(6). e202100575–e202100575. 6 indexed citations
13.
Tomašič, Tihomir, Žiga Jakopin, Hakon Leffler, et al.. (2021). Selective Monovalent Galectin‐8 Ligands Based on 3‐Lactoylgalactoside. ChemMedChem. 17(3). e202100514–e202100514. 7 indexed citations
14.
15.
Anderluh, Marko, et al.. (2020). CCK2R antagonists: from SAR to clinical trials. Drug Discovery Today. 25(8). 1322–1336. 10 indexed citations
16.
Tomašič, Tihomir, Said Rabbani, Roman P. Jakob, et al.. (2020). Does targeting Arg98 of FimH lead to high affinity antagonists?. European Journal of Medicinal Chemistry. 211. 113093–113093. 10 indexed citations
17.
Zhang, Hao, et al.. (2018). Inhibition of O-GlcNAc transferase (OGT) by peptidic hybrids. MedChemComm. 9(5). 883–887. 20 indexed citations
18.
Tomašič, Tihomir, et al.. (2018). Application of fragment based virtual screening towards inhibition of bacterial N- acetyglucosaminidase $. SAR and QSAR in environmental research. 29(9). 647–660. 2 indexed citations
19.
Anderluh, Marko, et al.. (2009). Synthesis of C6-ethylidene meropenem derivative with antimicrobial activity. Acta chimica slovenica. 56(3). 669–673. 4 indexed citations
20.
Anderluh, Marko & Marija Sollner Dolenc. (2002). Thrombin Receptor Antagonists, Recent Advances in PAR-1 Antagonist Development. Current Medicinal Chemistry. 9(13). 1229–1250. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sonsoles Martín‐Santamaría Breakdown of academic impact, for papers by Tihomir Tomašič Breakdown of academic impact, for papers by Andreas Larsson Breakdown of academic impact, for papers by Koji Tomita Breakdown of academic impact, for papers by Nickolay Y. Chirgadze Breakdown of academic impact, for papers by Arnab K. Chatterjee Breakdown of academic impact, for papers by Yuzuru Akamatsu Breakdown of academic impact, for papers by Louis Grenier Breakdown of academic impact, for papers by Ramón Hurtado‐Guerrero Breakdown of academic impact, for papers by Debashis Mitra
Rankless by CCL
2026